Claims for Patent: 10,058,593

Summary for Patent: 10,058,593

Title:	Methods and compositions for oral administration of proteins
Abstract:	This invention provides compositions that include a protein and at least two protease inhibitors, method for treating diabetes mellitus, and methods for administering same, and methods for oral administration of a protein with an enzymatic activity, including orally administering same.
Inventor(s):	Kidron; Miriam (Jerusalem, IL)
Assignee:	Oramed Ltd. (Jerusalem, IL)
Application Number:	12/934,754
Patent Claims:	1. An oral pharmaceutical composition comprising a protein and two protease inhibitors in a pharmaceutically acceptable formulation, wherein said protein is insulin, Exenatide, somatotropin, insulin growth factor-I, an oxidoreductase, a transferase, a hydrolase, a lyase, an isomerase, a ligase, an annexin, an ATP-binding cassette transporter, hemoglobin, an ATPase, a calcium channel, a potassium channel, a sodium channel, a solute carrier, an albumin, lactoglobulin, casein, ovomucin, ferritin, phosvitin, lactoferrin, vitellogenin, amyloid, collagen, elastin, fibrillin or glucagon, wherein said protease inhibitors consist of Soybean Trypsin Inhibitor (SBTI) and aprotinin, wherein said protease inhibitors increase the bioavailability of said protein when the composition is administered orally to a subject and wherein the oral pharmaceutical composition comprises a pharmaceutically acceptable carrier. 2. The oral pharmaceutical composition of claim 1, wherein said protein is insulin. 3. The oral pharmaceutical composition of claim 1, wherein said protein is Exenatide. 4. The oral pharmaceutical composition of claim 1, wherein said protein is a recombinant protein. 5. The oral pharmaceutical composition of claim 1, further comprising an omega-3 fatty acid. 6. The oral pharmaceutical composition of claim 5, wherein said omega-3 fatty acid is derived from fish oil. 7. The oral pharmaceutical composition of claim 1, further comprising a substance that enhances absorption of said protein through an intestinal mucosal barrier. 8. The oral pharmaceutical composition of claim 7, wherein said substance is EDTA or a salt thereof. 9. The oral pharmaceutical composition of claim 7, wherein said substance is a bile acid or alkali metal salt thereof. 10. The oral pharmaceutical composition of claim 1, further comprising a coating, that inhibits digestion of said oral pharmaceutical composition in a stomach of a subject. 11. The oral pharmaceutical composition of claim 10, wherein said coating is an enteric coating. 12. The oral pharmaceutical composition of claim 1, further comprising fish oil. 13. The oral pharmaceutical composition of claim 1, further comprising a gelatin coating. 14. The oral pharmaceutical composition of claim 1, wherein the presence of said protease inhibitors increases the bioavailability of said protein in a human subject. 15. The oral pharmaceutical composition of claim 2, wherein said protein is glucagon. 16. The oral pharmaceutical composition of claim 1, wherein said protein is said somatotropin or insulin growth factor-I. 17. The oral pharmaceutical composition of claim 1, wherein said protein is said oxidoreductase, transferase, hydrolase, lyase, isomerase or ligase. 18. The oral pharmaceutical composition of claim 1, wherein said protein is said annexin, ATP-binding cassette transporter, hemoglobin, ATPase, calcium channel, potassium channel, sodium channel or solute carrier. 19. The oral pharmaceutical composition of claim 1, wherein said storage protein is said albumin, lactoglobulin, casein, ovomucin, ferritin, phosvitin, lactoferrin, or vitellogenin. 20. The oral pharmaceutical composition of claim 1, wherein said protein is said amyloid, collagen, elastin or fibrillin. 21. An oral pharmaceutical composition comprising insulin and two protease inhibitors in a pharmaceutically acceptable formulation, wherein said protease inhibitors consist of Soybean Trypsin Inhibitor (SBTI) and aprotinin, wherein said protease inhibitors increase the bioavailability of said insulin when the composition is administered orally to a human subject and wherein the oral pharmaceutical composition comprises a pharmaceutically acceptable carrier. 22. The oral pharmaceutical composition of claim 21, further comprising an omega-3 fatty acid. 23. The oral pharmaceutical composition of claim 22, wherein said omega-3 fatty acid is derived from fish oil. 24. The oral pharmaceutical composition of claim 21, further comprising a substance that enhances absorption of said protein through an intestinal mucosal barrier. 25. The oral pharmaceutical composition of claim 24, wherein said substance is EDTA or a salt thereof. 26. The oral pharmaceutical composition of claim 24, wherein said substance is a bile acid or alkali metal salt thereof. 27. The oral pharmaceutical composition of claim 21, further comprising a coating that inhibits digestion of said oral pharmaceutical composition in a stomach of a subject. 28. The oral pharmaceutical composition of claim 27, wherein said coating is an enteric coating. 29. An oral pharmaceutical composition comprising Exenatide and two protease inhibitors in a pharmaceutically acceptable formulation, wherein said protease inhibitors consist of Soybean Trypsin Inhibitor (SBTI) and aprotinin, wherein said protease inhibitors increase the bioavailability of said Exenatide when the composition is administered orally to a human subject and wherein the oral pharmaceutical composition comprises a pharmaceutically acceptable carrier. 30. The oral pharmaceutical composition of claim 29, further comprising an omega-3 fatty acid. 31. The oral pharmaceutical composition of claim 30, wherein said omega-3 fatty acid is derived from fish oil. 32. The oral pharmaceutical composition of claim 29, further comprising a substance that enhances absorption of said protein through an intestinal mucosal barrier. 33. The oral pharmaceutical composition of claim 32, wherein said substance is EDTA or a salt thereof. 34. The oral pharmaceutical composition of claim 32, wherein said substance is a bile acid or alkali metal salt thereof. 35. The oral pharmaceutical composition of claim 29, further comprising a coating that inhibits digestion of said oral pharmaceutical composition in a stomach of a subject. 36. The oral pharmaceutical composition of claim 35, wherein said coating is an enteric coating. 37. An oral pharmaceutical composition comprising glucagon and two protease inhibitors in a pharmaceutically acceptable formulation, wherein said protease inhibitors consist of Soybean Trypsin Inhibitor (SBTI) and aprotinin, wherein said protease inhibitors increase the bioavailability of said glucagon when the composition is administered orally to a human subject and wherein the oral pharmaceutical composition comprises a pharmaceutically acceptable carrier. 38. The oral pharmaceutical composition of claim 37, further comprising an omega-3 fatty acid. 39. The oral pharmaceutical composition of claim 38, wherein said omega-3 fatty acid is derived from fish oil. 40. The oral pharmaceutical composition of claim 37, further comprising a substance that enhances absorption of said protein through an intestinal mucosal barrier. 41. The oral pharmaceutical composition of claim 40, wherein said substance is EDTA or a salt thereof. 42. The oral pharmaceutical composition of claim 41, wherein said substance is a bile acid or alkali metal salt thereof. 43. The oral pharmaceutical composition of claim 37, further comprising a coating that inhibits digestion of said oral pharmaceutical composition in a stomach of a subject. 44. The oral pharmaceutical composition of claim 43, wherein said coating is an enteric coating. 45. The oral pharmaceutical composition of claim 1, comprising a protein and two protease inhibitors in a pharmaceutically acceptable formulation, wherein said protein has a molecular weight of up to 10,000 Daltons, wherein said protease inhibitors consist of Soybean Trypsin Inhibitor (SBTI) and aprotinin, and wherein said protease inhibitors increase the bioavailability of said protein when the composition is administered orally to a subject. 46. The oral pharmaceutical composition of claim 45, wherein the protein has a molecular weight of up to 6,000 Daltons.

Details for Patent 10,058,593

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	TRASYLOL	aprotinin	Injection	020304	December 29, 1993	10,058,593	2029-02-26